2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1799

IgG Levels Correlate Inversely with Proteinuria Among Participants in the Abatacept and Cyclophosphamide Combination Therapy for Lupus Nephritis Trial, but Hypogammaglobulinemia Was Not Associated with an Increased Risk of Serious Infection
Abstract Number: 1800

A Novel Anti-CD28 Domain Antibody Antagonist Shows a Favorable Pharmacokinetic, Pharmacodynamic and Safety Profile
Abstract Number: 1801

Hydroxychloroquine Retinopathy: Application of the 2011 Screening Guidelines in an Academic Practice
Abstract Number: 1802

Hydroxychloroquine Level Variants and Predictors in a Connective Tissue Disease Population
Abstract Number: 1803

Serum Adipocyte Fatty Acid-Binding Protein Level Is Elevated in Patients with Systemic Lupus Erythematosus (SLE) but Not Associated with Biophysical Markers of Cardiovascular Disease
Abstract Number: 1804

Association of the Metabolic Syndrome (MetS) with Vascular Complications, End Stage Renal Failure (ESRF) and Mortality in Patients with Systemic Lupus Erythematosus (SLE): A Cohort Analysis
Abstract Number: 1805

Functional and Mechanistic Characterization of Anifrolumab, a Fully Human, Anti-IFNAR1 Monoclonal Antibody for the Treatment of Systemic Lupus Erythematosus
Abstract Number: 1806

Hydroxychloroquine Serum Levels and Flares of Systemic Lupus Erythematosus: A Longitudinal Cohort Analysis
Abstract Number: 1807

Estimated Sodium and Potassium Intake Are Associated with Blood Pressure in Patients with Systemic Lupus Erythematosus
Abstract Number: 1808

Exercise Is Associated with Improved Cardiometabolic Risk Factors in Patients with SLE
Abstract Number: 1809

Real Life Implementation of Lupus Nephritis Randomized Controlled Trials
Abstract Number: 1810

A Five-Year Follow-up of Microvascular Dysfunction and Coronary Artery Disease in SLE: Results from a Community-Based Lupus Cohort
Abstract Number: 1811

Depression and Progression of Subclinical Cardiovascular Disease in Systemic Lupus Erythematosus
Abstract Number: 1812

The First Randomized Control Trial to Evaluate the Effectiveness of Bortezomib for Refractory Systemic Lupus Erythematosus
Abstract Number: 1813

Novel Mechanism of Action of Anti-Malarial Drugs in the Inhibition of Type I Interferon Production

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].